192 related articles for article (PubMed ID: 25304249)
1. CD74 interferes with the expression of fas receptor on the surface of lymphoma cells.
Berkova Z; Wang S; Ao X; Wise JF; Braun FK; Rezaeian AH; Sehgal L; Goldenberg DM; Samaniego F
J Exp Clin Cancer Res; 2014 Oct; 33(1):80. PubMed ID: 25304249
[TBL] [Abstract][Full Text] [Related]
2. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.
Mao Y; Triantafillou G; Hertlein E; Towns W; Stefanovski M; Mo X; Jarjoura D; Phelps M; Marcucci G; Lee LJ; Goldenberg DM; Lee RJ; Byrd JC; Muthusamy N
Clin Cancer Res; 2013 Jan; 19(2):347-56. PubMed ID: 23209030
[TBL] [Abstract][Full Text] [Related]
3. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
Govindan SV; Cardillo TM; Sharkey RM; Tat F; Gold DV; Goldenberg DM
Mol Cancer Ther; 2013 Jun; 12(6):968-78. PubMed ID: 23427296
[TBL] [Abstract][Full Text] [Related]
4. Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex.
Wise JF; Berkova Z; Mathur R; Zhu H; Braun FK; Tao RH; Sabichi AL; Ao X; Maeng H; Samaniego F
Blood; 2013 Jun; 121(23):4729-39. PubMed ID: 23599269
[TBL] [Abstract][Full Text] [Related]
5. CD74 is expressed by multiple myeloma and is a promising target for therapy.
Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
[TBL] [Abstract][Full Text] [Related]
6. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
Stein R; Smith MR; Chen S; Zalath M; Goldenberg DM
Clin Cancer Res; 2009 Apr; 15(8):2808-17. PubMed ID: 19351768
[TBL] [Abstract][Full Text] [Related]
7. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression.
Frölich D; Blassfeld D; Reiter K; Giesecke C; Daridon C; Mei HE; Burmester GR; Goldenberg DM; Salama A; Dörner T
Arthritis Res Ther; 2012 Mar; 14(2):R54. PubMed ID: 22404985
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoprotein.
Berkova Z; Wang S; Wise JF; Maeng H; Ji Y; Samaniego F
J Natl Cancer Inst; 2009 Mar; 101(6):399-411. PubMed ID: 19276446
[TBL] [Abstract][Full Text] [Related]
9. Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells.
Gajate C; Gonzalez-Camacho F; Mollinedo F
PLoS One; 2009; 4(4):e5044. PubMed ID: 19352436
[TBL] [Abstract][Full Text] [Related]
10. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
Alinari L; Yu B; Christian BA; Yan F; Shin J; Lapalombella R; Hertlein E; Lustberg ME; Quinion C; Zhang X; Lozanski G; Muthusamy N; Prætorius-Ibba M; O'Connor OA; Goldenberg DM; Byrd JC; Blum KA; Baiocchi RA
Blood; 2011 Apr; 117(17):4530-41. PubMed ID: 21228331
[TBL] [Abstract][Full Text] [Related]
11. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
Alinari L; Mahoney E; Patton J; Zhang X; Huynh L; Earl CT; Mani R; Mao Y; Yu B; Quinion C; Towns WH; Chen CS; Goldenberg DM; Blum KA; Byrd JC; Muthusamy N; Praetorius-Ibba M; Baiocchi RA
Blood; 2011 Dec; 118(26):6893-903. PubMed ID: 22042694
[TBL] [Abstract][Full Text] [Related]
12. Surface expression of CD74 by type II alveolar epithelial cells: a potential mechanism for macrophage migration inhibitory factor-induced epithelial repair.
Marsh LM; Cakarova L; Kwapiszewska G; von Wulffen W; Herold S; Seeger W; Lohmeyer J
Am J Physiol Lung Cell Mol Physiol; 2009 Mar; 296(3):L442-52. PubMed ID: 19136583
[TBL] [Abstract][Full Text] [Related]
13. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3.
Wieder T; Essmann F; Prokop A; Schmelz K; Schulze-Osthoff K; Beyaert R; Dörken B; Daniel PT
Blood; 2001 Mar; 97(5):1378-87. PubMed ID: 11222383
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas.
Martin P; Furman RR; Rutherford S; Ruan J; Ely S; Greenberg J; Coleman M; Goldsmith SJ; Leonard JP
Leuk Lymphoma; 2015; 56(11):3065-70. PubMed ID: 25754579
[TBL] [Abstract][Full Text] [Related]
15. HLA class II-mediated death is induced via Fas/Fas ligand interactions in human splenic B lymphocytes.
Truman JP; Choqueux C; Tschopp J; Vedrenne J; Le Deist F; Charron D; Mooney N
Blood; 1997 Mar; 89(6):1996-2007. PubMed ID: 9058721
[TBL] [Abstract][Full Text] [Related]
16. LPS-mediated cell surface expression of CD74 promotes the proliferation of B cells in response to MIF.
Klasen C; Ziehm T; Huber M; Asare Y; Kapurniotu A; Shachar I; Bernhagen J; El Bounkari O
Cell Signal; 2018 Jun; 46():32-42. PubMed ID: 29476963
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B Virus X Protein Modulates Apoptosis in NRK-52E Cells and Activates Fas/FasL Through the MLK3-MKK7-JNK3 Signaling Pathway.
He P; Zhang B; Liu D; Bian X; Li D; Wang Y; Sun G; Zhou G
Cell Physiol Biochem; 2016; 39(4):1433-43. PubMed ID: 27606894
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity.
Micheau O; Solary E; Hammann A; Martin F; Dimanche-Boitrel MT
J Natl Cancer Inst; 1997 Jun; 89(11):783-9. PubMed ID: 9182976
[TBL] [Abstract][Full Text] [Related]
19. CpG oligonucleotides suppress HepG2 cells-induced Jurkat cell apoptosis via the Fas-FasL-mediated pathway.
Zheng J; Fu R; Li J; Wang X
J Exp Clin Cancer Res; 2011 May; 30(1):48. PubMed ID: 21535900
[TBL] [Abstract][Full Text] [Related]
20. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions.
Eischen CM; Kottke TJ; Martins LM; Basi GS; Tung JS; Earnshaw WC; Leibson PJ; Kaufmann SH
Blood; 1997 Aug; 90(3):935-43. PubMed ID: 9242521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
